



PRESS RELEASE

For Immediate Release: June 24th, 2009

Balerna (Switzerland) and Istanbul (Turkey)

Abdi Ibrahim Pharmaceuticals ("Abdi Ibrahim") and APR Applied Pharma Research SA ("APR"), together with its joint venture partner Labtec GmbH ("Labtec"), today announced that they have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm[®] in Turkey.

APR and the leading pharmaceutical company in Turkey Abdi Ibrahim have entered into an exclusive license agreement for the promotion, distribution and marketing of Ondansetron Rapidfilm[®] in Turkey; terms of the deal were not disclosed.

"It is an honour to work with a dedicated and professional company like APR. Ondansetron Rapidfilm[®] with its unique delivery system will be part of Abdi Ibrahim's oncology portfolio and is in line with our overall aim to bring new treatment alternatives for the Turkish patients" said Matthias Heidt, Business Development Director of Abdi Ibrahim. "As Abdi Ibrahim has a successful track record collaborating with almost 40 Licensors worldwide, we are convinced that the current agreement with APR will be the initiation for another long-lasting partnership strengthening our supportive care line for cancer patients".

"We are very proud that the leading Turkish company Abdi Ibrahim will market our Ondansetron Rapidfilm[®] in Turkey" said Paolo Galfetti CEO of APR. "This is an additional confirmation of our ability to add value through innovation: the agreement executed with Abdi Ibrahim is the last important step of a successful history of development & licensing for Ondansetron Rapidfilm[®] in Europe and in the rest of the world; Ondansetron Rapidfilm[®] is now licensed in 38 countries in the world including Europe where the product is currently under registration".

Ondansetron Rapidfilm[®] is an innovative oral thin film formulation for the prevention of chemotherapy induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting; registration approval in Europe is expected sometime in 2010.

Ondansetron Rapidfilm[®] consists of a thin film strip based on a water-soluble polymer. The film disintegrates rapidly within seconds in contact with water or saliva, releases the drug in the mouth and promotes gastrointestinal absorption. The Rapidfilm[®] dosage form was especially designed for high patient compliance. The administration is easy. The patient does not have any swallowing difficulty. The fact that no water intake after administration is needed is very well accepted by patients with nausea. Ondansetron is by far the top selling in its class of drugs used in the prevention and treatment of nausea and vomiting both in the United States and in the Top 5 European countries (where Ondansetron accounts for 67% of the total 5-HT₃ antagonists market).

Ondansetron Rapidfilm[®] is the first product of a more consistent pipeline of Rapidfilm[®] products in various stage of development including blockbuster molecules primarily



APPLIED PHARMA RESEARCH S.A.

targeting CNS indications like Donepezil and all based upon APR/Labtec's proprietary Rapidfilm® oral dosage form.

About Abdi Ibrahim Pharmaceuticals

Founded in 1912, Abdi Ibrahim Pharmaceuticals is a family owned company headquartered in Istanbul, Turkey, led by Pharmacist Mr. Nezir Barut in the third generation. Abdi Ibrahim Pharmaceuticals is ranked among the Top 100 corporations worldwide and is heading the Turkish Market for more than 6 years in value with a market share of 7% and for more than 8 years in units as of year 2008. With an annual turnover of 850 mn USD and presence in CEE regions, Abdi Ibrahim is already active in all major pharmaceutical segments including CNS, Respiratory, Cardiology, Rheumatology, Gastroenterology and Ophthalmology by licensed-in products or own developed generic products. Oncology and Biotechnology is a key area of Abdi Ibrahim's pipeline focus, where the company intends to reach a major position in Turkey within the next 5 years.

About APR Applied Pharma Research

APR Applied Pharma Research s.a. is a private, independent R&D Healthcare company headquartered in Switzerland. The company focuses its efforts on the development of its own selected drug candidates (developed using APR proprietary technologies) as well as on the development under contract of third party pharmaceutical products and medical devices. Leveraging on its own technology platforms, R&D know-how, marketing and regulatory systems, APR is committed to create new sustainable value on its own as well as on third party products and projects. The APR products and technologies are licensed to third parties for distribution and marketing and APR has entered licensing agreements with pharmaceutical companies in more than 100 countries worldwide and its sales are almost totally achieved abroad.

About Labtec GmbH

Founded in 1990 as an independent start-up company, Labtec GmbH quickly became one of the leading drug delivery development companies in the transdermal and topical patch arena as well as with oral films in Europe.

In 2008 Labtec became a 100% subsidiary of tesa SE and today represents their pharmaceutical business.

For any further information please contact:

Abdi Ibrahim Pharmaceuticals,
Matthias Heidt; Business Development Director
Email: matthias.heidt@abdiibrahim.com.tr
Reşitpaşa Mahallesi
Eski Büyükdere Caddesi.No:4
PK.34467-Maslak/Sariyer/, Istanbul, Turkey
T: +90 212 366 85 15
www.abdiibrahim.com.tr



APPLIED PHARMA RESEARCH S.A.

APR Applied Pharma Research s.a.,
Paolo Galfetti; CEO
Email: paolo.galfetti@apr.ch
Via Corti 5, CH - 6828 Balerna, Switzerland
T: +41 91 6957020
www.apr.ch

Labtec GmbH,
Dr. Ingo Lehrke; Managing Director
Email: ingo.lehrke@labtec-pharma.com
Raiffeisenstrasse 4, D-40764 Langenfeld, Germany
T: +49 2173 9735-0
www.labtec-pharma.com/